Urologic surgeon Bernard Bochner discusses the prevalence of bladder cancer in the United States, and novel approaches to treatment.
Medical oncologist Dean Bajorin describes novel chemotherapy drugs in development at Memorial Sloan Kettering that may be given before bladder cancer surgery.
Medical oncologist Dean Bajorin talks about combining chemotherapy or radiation with surgery to treat patients with advanced bladder cancer.
Our team of specialists in urology, medical oncology, urologic surgery, radiation oncology, pathology, and radiology diagnose and treat nearly 400 patients with bladder cancer annually. In addition to expertise in minimally invasive surgery for noninvasive bladder cancer and post-operative Calmette-Guérin (BCG) therapy for patients at high risk of recurrence, our urologic surgeons have extensive experience in cystectomy for invasive bladder cancer; we perform approximately 250 radical cystectomy operations each year.
We also offer a range of bladder preservation and reconstructive options and are working to develop new techniques to further improve radiation therapy via intensity-modulated radiation therapy (IMRT) and image-guided radiotherapy (IGRT). Our first-line treatment for metastatic bladder cancer includes standard chemotherapy regimens as well as access to novel drug regimens through clinical trial enrollment.